Background: Platelet reactivity is a well-established determinant of clinical outcomes after percutaneous coronary intervention (PCI). Conflicting data have been reported concerning the impact of chronic kidney disease (CKD) on residual platelet reactivity (PR) on clopidogrel in patients with coronary artery disease (CAD) undergoing PCI. Aim of the present study was to compare PR and its association with clinical outcomes after PCI in CAD patients with and without CKD. Methods: In 800 patients treated with clopidogrel we measured PR with the VerifyNow P2Y12 Assay immediately before PCI (results given as P2Y12 reaction units [PRU]). According to previous studies, we defined HPR as a PRU value Ն240 and LPR and a PRU value Յ178. CKD was defined as a glomerular filtration rate Ͻ60 ml/min/1.73 m 2 . Clinical follow-up at 30 days was obtained in all patients. Net adverse clinical events (NACE) were considered as ischemic (death, myocardial infarction and target vessel revascularization) and bleeding events (according to TIMI criteria). Results: Patients with (nϭ173, 21.6%) and without CKD showed similar PRU values (208Ϯ67 vs. 207Ϯ75; pϭ0.819). The incidence of 30-day ischemic (12.1% vs. 7.2%; pϭ0.036) and bleeding events (8.7% vs. 2.1%; pϽ0.001) was higher in the CKD group. The presence of HPR was associated with higher rates of ischemic events in both patients with (21.1% vs. 7.6%; pϭ0.012) and without CKD (12.6% vs. 4.7%; pϽ0.001). Likewise, LPR was associated with higher rates of bleeding in both patients with (19.3% vs. 3.4%; pϽ0.001) and without CKD (5.1% vs. 0.5%; pϽ0.001). NACE were significantly higher in CKD patients with HPR or LPR (25.4%) and lowest in those without CKD, HPR or LPR (6.6%; p for trend Ͻ0.001). At multivariate analysis, the combination of CKD with LPR or HPR was the strongest predictor of NACE (odds ratio 3.4, 95% confidence interval 2.0-5.6; pϽ0.001).
Background: Acute kidney injury (AKI) is a potentially serious complication of transcatheter aortic valve implantation (TAVI) that has recently been re-defined by the Valve Academic Research Consortium (VARC). The aim of this study was to identify the incidence and risk factors for AKI after TAVI. Methods: We performed a retrospective analysis of data from 248 consecutive patients undergoing TAVI using the Edwards bioprosthesis at St Thomas' Hospital, London, UK. AKI was defined as a VARC-modified Risk, Injury, Failure, Loss, and End-stage (RiFLE) kidney disease score Ն2. Results: Of 248 patients who underwent TAVI using the Edwards bioprosthesis 89 (35.9%) of patients suffered an acute kidney injury as defined by the a score of Ն2 on the VARC-modified RiFLE score. The overall mean pre-procedural creatinine was 116.6Ϯ69.3 mol/L with an overall peak creatinine of 148.8Ϯ94.4 mmol/L (pϽ0.001). Patients with AKI had greater mean pre-procedural (134.7Ϯ74.5 v. 106.5Ϯ64.2 mmol/L (pϽ0.001), 48h (206.8Ϯ89.1 v. 98.0Ϯ40.0 mmol/L (pϽ0.001)) and 72h creatinine concentrations (205.9Ϯ88.3 v. 99.3Ϯ39.6 mmol/L (pϽ0.001)). A higher VARCmodified RiFLE score was associated with increased mortality (pϽ0.001). Kaplan Meier analysis according to incidence of RiFLE score Ն2 (i.e. AKI) demonstrated significantly increased mortality at 30 days (13.5% v. 3.8%), 1 year (31.5% v. 15.0%) and overall (40.4% v. 19.5%; logrank pϽ0.001) at a median follow up of 379 days (interquartile range 113-729 days). Multivariate logistic regression analysis revealed that the variable with the strongest independent association with risk of AKI was DM (OR 3.17, 95%CI 1.67-6.05, pϽ0.001), followed by peripheral vascular disease (OR 2.54, 95%CI 1.34-6.44, pϭ0.007) and the pre-procedural stage of chronic kidney disease (OR 1.57, 95%CI 1.11-2.21, pϭ0.010). Conclusions: Greater than 1/3 of patients sustain AKI after TAVI using the Edwards bioprosthesis, as defined by the VARC-modified RiFLE score. AKI was associated with increased mortality at both 30-days and at 1-year. A history of diabetes mellitus, peripheral vascular disease and higher chronic kidney disease stage had the strongest independent associations with post-TAVI AKI.
TCT-146

The Effect of Drug-Eluting Stents on Clinical and Angiographic Outcomes in Renal Failure Patients with Dialysis: Multicenter Registry in Asia
Sunao Nakamura 1 , Hisao Ogawa 2 , Jang-Ho Bae 3 , Yeo Cahyadi 4 , Wasan Udayachalerm 5 , Damras Tresukosol 6 , Sudaratana Tansuphaswadikul 7 1 New Tokyo Hospital, Chiba, Japan, 2 Kumamoto University Hospital, Kumamoto, Japan, 3 Konyang University Hospital, Daejeon, Korea, Republic of, 4 Husada Hospital, Jakarta, Indonesia, 5 King Chulalongkorn Memorial Hospital, Bangkok, Thailand, 6 Faculty of Medicine Siriraj Hospital, Bangkok, Thailand, 7 Chest Disease Institute, Nonthaburi, Thailand Background: Patients treated with renal failure have been reported having high incidence of mortality and other complications rate after PCI. Optimal treatment of PCI for renal failure patients with dialysis is still unknown. Aim: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), EPC capture (ECS), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES) and Everolimus-eluting stent (EES) on the outcome of percutaneous coronary intervention in renal failure patients with dialysis (CRF-HD). Methods: A prospective analysis of 1013 patients with CRF-HD (258 SES, 244 PES, 77 ECS, 118 ZES-R, 128 BES, 188 EES) in six high volume Asian centers after successful stenting was performed. The study endpoints were 30 days major adverse cardiac events (MACE) and 12, 24 and 36 months target lesion revascularization (TLR) and MACE. Results: The baseline clinical characteristics between 5 groups were similar. See table for clinical results. Conclusions: The use of drug-eluting stents in patient with CRF-HD was safe with low acute complication. Patients treated with PES and EES showed lesser incidence of restenosis rate and TLR compared with other drug-eluting stents. We studied whether atorvastatin 80mg loading and subsequent use for 5days (high dose group[HD]) could prevent CIN as compared to those received atorvastatin 10mg (routine dose group[RD]) with same schedule in patients with ST-elevation myocardial infarction undergoing primary angioplasty. Primary endpoint was incidence of CIN, defined as a Ն 25% or Ն 0.5 mg/dL increase in baseline serum creatinine within 5 days after contrast administration. Secondary endpoint was 1-and 6-month renal function change and composite of all cause mortality, renal failure, heart failure and target vessel revascularization. Results: One hundred and ten patients were allocated to HD and 108 to RD from August 2007 to February 2009. CIN incidence was 5.5% (6/110) in HD and 10.2% (11/108) in RD, a nonsignificant difference (pϭ0.193). CIN occurred significantly less in HD than RD, 0% vs. 16.7% (pϭ0.024) in subgroups of renal insufficiency (creatinine clearance [CrCl]Յ60mL/min) and 4% (1/25) and 23.1% (6/26) respectively, (pϭ0.048) in old patientsՆ70. Composite of clinical outcomes at 6-month was comparable in HD and RD (7.9% and 13.1%, pϭ0.26). CrCl rat 1-month tended to be higher, in HD than in RD, 81 TUESDAY, OCTOBER 23, 8:00 AM-10:00 AM www.jacc.tctabstracts2012.com Background: Blood transfusion is associated with acute kidney injury (AKI) after transcatheter aortic valve implantation (TAVI). We sought to elucidate in more detail the relation between blood transfusion and AKI and its effects on short-and long-term mortality. Potential triggers of blood transfusion such as baseline anemia, bleeding-vascular complications and peri-operative blood loss were not identified as predictors. Patients with severe baseline anemia had 2.4 times less blood loss but on average received 2.3 fold more units of blood transfusions in comparison to patients without anemia before TAVI (pϽ0.001). AKI and life-threatening bleeding were independent predictors of 30-day mortality (OR: 3.04 [1.52-6.07], OR: 5.39 [2.14-13.57], respectively) while transfusion (Ն3 units), baseline anemia and AKI predicted mortality beyond 30 days. Conclusions: AKI occurred in 21% of the patients after TAVI. The number of blood transfusions but not the indication of transfusion predicted AKI. AKI was a predictor of both short-and long-term mortality whereas blood transfusion predicted long-term mortality. These findings indicate that outcome of TAVI may be improved by more restrictive use of blood transfusions.
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Impact of Chronic Kidney Disease on Myocardial Infarct Size and Adverse Events in ST-Elevation Myocardial Infarction: Results from the INFUSE-AMI Trial
Usman Baber 1 , Roxana Mehran 2 , Sorin Brener 3 , Akiko Maehara 4 , Dariusz Dudek 5 , Thomas Neunteufl 6 , D. Christopher Metzger 7 , C. Michael Gibson 8 , Gregg Stone 9 1 Mount Sinai School of Medicine, New York, NY, 2 Mount SInai School of Medicine, New York, NY, 3 New York Methodist Hospital, Brooklyn, NY, 4 Cardiovascular Reserach Foundation and Columbia University Medical Center, New York, NY, 5 University Hospital, Krakow, Poland, 6 AKH Vienna Austria, Vienna, Vienna, 7 Wellmont CVA Heart Institute, Kingsport, USA, Boston, USA, 9 Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY Background: Chronic kidney disease (CKD) patients have less favorable outcomes after ST-elevation myocardial infarction (STEMI) for yet unclear reasons. Methods: The INFUSE-AMI trial randomized patients with STEMI due to proximal or mid LAD occlusion to intracoronary bolus abciximab (ClearWay RX catheter) vs. no abciximab, and to thrombus aspiration (Export) vs. no aspiration. We compared infarct size as % of LV mass assessed by magnetic resonance imaging at 30-days, myocardial reperfusion and incidence of adverse events between patients with vs. patietns without CKD. CKD was defined as a creatinine clearance Ͻ 60 ml/min. Results: Patients with CKD (nϭ59, 14.4%) were older, more often female, diabetic and less likely to undergo angiography within 3 hours of symptom onset (50.8% vs. 72.2%, pϭ0.001) compared to those without CKD (nϭ349, 85.5%). Following PCI, final thrombolysis in myocardial infarction (TIMI) 3 flow (86.4 vs. 92.8%, pϭ0.12) and myocardial blush grade (MBG) 3 (64.4% vs. 70.5%, pϭ0.35) was observed similarly in both groups. Median infarct size was non-significantly larger in CKD patients (19.3% vs. 17.0%, pϭ0.34) . The incidence of 30-day adverse events, were significantly higher in those with CKD (Figure) . There were no significant differences in stent thrombosis, reinfarction or revascularization between groups.
Conclusions:
Differences in infarct size between patients with and without CKD presenting with STEMI are modest and unlikely to account for the significantly higher short-term cardiac risk in those with CKD.
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Prognostic Value of Different Definitions of Contrast Induced Acute Kidney Injury in STEMI: Analysis from the HORIZONS-AMI Trial
Rudolf Jarai 1 , George Dangas 2 , Kurt Huber 3 , Roxana Mehran 4 , Gregg Stone 5 , Ke Xu 6 1 Wilhleminenhospital, Vienna, Austria, 2 Department of Cardiology, Mount Sinai Medical Center, New York, New York City, NY, 3 Dept Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria, Vienna, Austria, 4 Mount Sinai Hosptial, New York, USA, 5 Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, 6 Cardiovascular Research Foundation, New York, NY Background: Several definitions of acute kidney injury (AKI) are in use, and the optimal absolute and relative increase of serum creatinine increase after contrast administration to define contrast-media induced acute kidney injury (CI-AKI) is still a matter of debate. Moreover, the prognostic relevance of AKI according to the varying definitions in STEMI has not been established. Methods: Serum creatinine concentration data within 48h after coronary angiography was present in 2975 STEMI pts in the HORIZONS-AMI trial. Patients were analyzed according to different AKI definitions (AKIN-, modified AKIN-(mAKIN), Waikar-Bonventre (W-B), percent-changes of creatinine (Ͻ25%, 26-50%; 51-75%; Ͼ75%) and to the commonly used "standard-definition" of a relative increase in serum creatinine of Ն25% or an absolute increase of Ն0.5 mg/dL). The primary endpoint was all-cause mortality at 3 years. Results: Depending on definitions the incidence of CI-AKI ranged from 5.0% to 15.5%. Similarly, 3-year mortality rates differed substantially with respect to the different CI-AKI definitions (Table) . Absolute changes of creatinine were strongly associated with all-cause mortality, starting with an increase of 0.3mg/dl absolute increase of creatinine above baseline (HR 3.68 pϽ0.001; Figure) -the cutoff level used in the AKIN-and modified AKIN-definitions. The increased risk associated with Ͼ0.3mg/dl absolute increase of creatinine was independent of the amount of contrast-media used. 
